Evidence map›Paper›PMID 28985996›Full record

ArticleCytokine2018

TLR-induced secretion of novel cytokine IL-27 is defective in newly diagnosed type-2 diabetic subjects.

Haridoss Madhumitha, Viswanathan Mohan, Subash Babu, Vivekanandhan Aravindhan

Abstract read
In one paragraph

Article in Cytokine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Role of Interleukins in Type 1 and Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Haridoss MadhumithaAU-KBC Research Centre, MIT Campus of Anna University, Chennai 600 044, India.
Viswanathan MohanMadras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialties Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, International Diabetes Federation (IDF) Centre of Education, Chennai, India.
Subash BabuNational Institute of Health-International Centre for Excellence in Research, National Institute for Research in Tuberculosis, Chennai, India.
Vivekanandhan AravindhanDept of Genetics, Dr. ALM PG IBMS, University of Madras, Taramani, Chennai 600 113, India. Electronic address: cvaravindhan@gmail.com.
Anna University, Chennai · INMadras Diabetes Research Foundation · INNational Institute of Research in Tuberculosis · INUniversity of Madras · IN

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Toll-like receptors (TLRs), the innate immune receptors, act as sentinels bridging both innate and adaptive arms of immunity. In the present study, we estimated TLR-induced secretion of IL-27, IL-12, IL-23, IL-8, IP-10, IL-17, IL-6 and TNF-α (by ELISA) and expression of Human Leukocyte Antigen- (Human Leukocyte Antigen - antigen D Related (HLA-DR), CD69, CD80 (also known asB7-1) (by flowcytometry) and Activating Transcription Factor 3(ATF3) (by qRT-PCR) in whole blood cultures of control and type-2 diabetic (both newly diagnosed/NDD and known/KDM) subjects. TLR-induced secretion of IL-27 was significantly reduced in the NDD group compared to the control (Normal Glucose Tolerance (NGT)) and KDM groups. On the other hand, the expression of CD80 was significantly upregulated in both the monocytes and B cells in KDM group. This was associated with increased T cell activation (CD3+CD69+HLA-DR+) with increased IL-17 and reduced TNF-α secretion in this group. Impaired TLR-induced IL-27 secretion and augmented expression of antigen presentation molecules result in chronic T cell activation which may fuel T cell-mediated inflammation in type-2 diabetes.

Indexed as

B7-1 AntigenB-LymphocytesCell PolarityDiabetes Mellitus, Type 2HLA-DR AntigensHumansInterleukin-17Interleukin-27Lymphocyte ActivationMonocytesT-Lymphocytes, Helper-InducerToll-Like ReceptorsTumor Necrosis Factor-alphaB7-1 AntigenHLA-DR AntigensInterleukin-17Interleukin-27Toll-Like ReceptorsTumor Necrosis Factor-alphaCD80HLA-DRIL-27TLRType-2 diabetes

Identifiers

PMID28985996
PMCPMC6367208
OpenAlexW2763751155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.